Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).

Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
复制标题

DOI:
10.1371/journal.pone.0121177
复制
发表时间:
2015
期刊:
影响因子:
3.7
通讯作者:
Kuriyan J
Kuriyan J
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Zorn JA;Wang Q;Fujimura E;Barros T;Kuriyan J

文献摘要

参考文献

被引文献

相似文献

超过 30% 的急性髓系白血病 (AML) 患者的受体酪氨酸激酶 FMS 样酪氨酸激酶 3 或 FLT3 具有激活突变。目前正在进行临床试验的 FLT3 小分子抑制剂(称为 quizartinib 或 AC220)似乎有望用于治疗 AML。在这里,我们报告了 FLT3 激酶结构域与 quizartinib 复合物的共晶结构。与 quizartinib 结合的 FLT3 采用“Abl 样”非活性构象,激活环稳定在“DFG-out”方向并折叠回激酶结构域。这种构象与在 FLT3 的非复合胞内结构域以及相关受体酪氨酸激酶中观察到的构象相似,除了激活环中的局部诱导拟合之外。共晶结构揭示了 quizartinib 和 FLT3 活性位点之间的相互作用,这是实现其针对野生型 FLT3 以及在许多 AML 患者中观察到的 FLT3 变体的高效效力的关键。该复合物进一步为 quizartinib 耐药突变提供了结构原理。
More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML. Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib. FLT3 with quizartinib bound adopts an “Abl-like” inactive conformation with the activation loop stabilized in the “DFG-out” orientation and folded back onto the kinase domain. This conformation is similar to that observed for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop. The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant observed in many AML patients. This co-complex further provides a structural rationale for quizartinib-resistance mutations.
DOI: 10.1532/ijh97.05079
发表时间: 2005-08-01
影响因子: 2.1
作者:
Levis, M;Small, D
通讯作者: Small, D
DOI: 10.1093/bioinformatics/btt055
发表时间: 2013-04-01
期刊: BIOINFORMATICS
影响因子: 5.8
作者:
Pronk, Sander;Pall, Szilard;Lindahl, Erik
通讯作者: Lindahl, Erik
DOI: 10.1107/s0907444904019158
发表时间: 2004-12-01
影响因子: 2.2
作者:
Emsley, P;Cowtan, K
通讯作者: Cowtan, K
DOI: 10.1038/nchembio799
发表时间: 2006-07-01
影响因子: 14.8
作者:
Liu, Y;Gray, NS
通讯作者: Gray, NS
DOI: 10.1107/s0907444909052925
发表时间: 2010-02
期刊: Acta crystallographica. Section D, Biological crystallography
影响因子: --
作者:
Adams PD;Afonine PV;Bunkóczi G;Chen VB;Davis IW;Echols N;Headd JJ;Hung LW;Kapral GJ;Grosse-Kunstleve RW;McCoy AJ;Moriarty NW;Oeffner R;Read RJ;Richardson DC;Richardson JS;Terwilliger TC;Zwart PH
通讯作者: Zwart PH